Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.51 |
| ▸ | BCR | P11274 | 12/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | FES | P07332 | 1/20 | 0.42 |
| ▸ | HCK | P08631 | 1/20 | 0.42 |
| ▸ | FER | P16591 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28821018 | 0.81 | ABL1 (0.49) | ABL1BCRGRM5ALDH1A1 | |
| SCHEMBL374708 | 0.80 | HCK (0.58) | ABL1BCRSMN1; SMN2HCK | |
| SCHEMBL374474 | 0.80 | METTL3 (0.47) | ABL1BCRCDK9ALDH1A1SMN1; SMN2 | |
| SCHEMBL374182 | 0.75 | EGFR (0.49) | ABL1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4724653 | 0.75 | NPC1 (0.55) | SMN1; SMN2 | |
| SCHEMBL4947956 | 0.74 | KIT (0.46) | ABL1BCRHCK | |
| SCHEMBL22531924 | 0.73 | CD274 (0.53) | — | |
| SCHEMBL14659640 | 0.73 | HCK (0.43) | ABL1BCRCDK9ALDH1A1SMN1; SMN2 | |
| SCHEMBL374541 | 0.72 | TNNI3K (0.47) | ABL1BCRCDK9ALDH1A1MAP3K7 | |
| SCHEMBL4947981 | 0.72 | HCK (0.51) | ALDH1A1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-04-21 | — | — | US | disclosed |
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-04-21 | — | — | US | disclosed |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2019-03-21 | — | — | US | disclosed |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2019-03-21 | — | — | US | disclosed |
| EP-3324970-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | Taipei Medical University (TW) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015400-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-01-26 | — | — | WO | disclosed |
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | ABL1 9/4885BCR 356/4885PRKAA2 633/4885 |
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | MKI67, CTCF, CDKN1A | ABL1 36/4885BCR 311/4885PRKAA2 2907/4885 |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | MKI67, CTCF, CDKN1A | ABL1 36/4885BCR 311/4885PRKAA2 2907/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | ABL1 9/4885BCR 356/4885PRKAA2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.